The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.
April 29th 2024
A new study found a 2-week mindfulness-based intervention for patients with psoriasis does not improve skin status—it only helps the mind.
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Advances In™: Aligning Pathology and Oncology Efforts in the Community to Improve NSCLC Care
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Reviewing Potential Atopic Dermatitis Treatments and Pathogeneses
A recent review of current research on atopic dermatitis (AD) treatments found that a clearer understanding of the pathogenesis of the phenotypes involved in the disease will lead to advances in new therapies.
Long-Term Secukinumab Treatment Safe and Effective for Patients with Psoriatic Arthritis
Patients with active psoriatic arthritis treated with secukinumab for 2 years in the FUTURE-1 trial experienced sustained decreases in disease activity and symptoms, leading to improvements in physical function and quality of life.
New Trials Bolster Dupilumab's “First Line Treatment†Potential for Atopic Dermatitis
Eric Simpson, MD, the lead author on the study, spoke to MD Magazine about the results, which showed great improvement with few side effects for those with moderate or severe atopic dermatitis.
Too Many Ways to Measure an Itch, Derm Study Finds
October 12th 2016Dermatitis researchers use far too many instruments in measuring symptoms of skin ailments, a study found. Symptoms of atopic ezcema/dermatitis (AD) were found in a systematic review of randomized controlled trials (RCTs) to be most often characterized from composite measures rather than stand-alone symptom severity rating instruments, and thirty different instruments were found to have been used across 378 trials.
Early Subcutaneous Allergen Immunotherapy Works for Certain Patients
October 12th 2016Severe atopic dermatitis (AD) symptoms of shorter duration were more likely to improve in allergen sensitized patients receiving desensitizing immunotherapy, than severe symptoms of longer duration or more moderate symptoms, according to a new observational cohort study.
Atopic Dermatitis: Immunotherapy Can Be Effective
October 10th 2016Severe atopic dermatitis (AD) symptoms of shorter duration were more likely to improve in allergen sensitized patients receiving desensitizing immunotherapy, than severe symptoms of longer duration or more moderate symptoms, according to a new observational cohort study.
Which Patients with Atopic Dermatitis Are Least Likely to Outgrow It?
October 6th 2016Childhood atopic dermatitis (AD) usually resolves before adulthood, a meta-analysis of cases showed. Those patients who did see their AD persist were more likely to be female, to have been older at onset, and to have relatively severe AD.
Obesity May Exacerbate Psoriatic Arthritis Risks, Limit TNFI Effectiveness
Analysis of patient records from Denmark and Iceland found that obese psoriatic arthritis patients responded less than their lighter counterparts to tumor necrosis factor inhibitors (TNFIs) and that they used such medications for shorter periods of time.
Study Endorses Early TNF Use in Patients with Psoriasis
A new model that combines real-world prices with outcome data from both controlled trials and clinical practice indicates that the immediate use of tumor necrosis factor inhibitors (anti-TNFs) is a cost-effective way to achieve good first-year outcomes in patients newly diagnosed with both plaque psoriasis and psoriatic arthritis.
Assessing Links Between Tobacco Smoke and Atopic Dermatitis
Across the board, researchers saw that studies of active smokers showed increased prevalence of the skin condition, regardless of age or region. It isn't quite clear, though, whether smoking causes AD or AD causes people to smoke.